Channel Therapeutics Corporation (CHRO)
Channel Therapeutics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Freehold, NJ, US. The stock last traded at $1.35, up 7.14% on the session, giving a market capitalisation of $8.9M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -186.2%. Its beta of 3.29 implies it has historically moved more than the broad market.
Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation. This compound is being explored for its potential efficacy in treating erythromelalgia and diverse forms of neuropathic pain. Founded in 2002, this New Jersey-based entity maintains its corporate headquarters in Freehold.
Channel Therapeutics Corporation is most often compared with the following Healthcare names: